Codexis (NASDAQ: CDXS)
Codexis Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Codexis Company Info
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
News & Analysis
Up Over 500% in the Last 5 Years, Can This Biotech Continue Its Hot Streak?
Codexis is leveraging its core technology to create more effective life science tools.
Codexis Dodges Coronavirus Slowdown in Q2
R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.
Should Codexis Investors Prepare for Slower Growth?
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
Near a 2-Year Low, Is Codexis Stock a Buy?
The small-cap stock has been cut in half in the last year. Is a $650 million market cap too good to pass up?
Codexis Expects Its Most Important Source of Revenue to Decline in 2020
The company expects a fourth straight year of stagnant product revenue -- and declining gross margin, to boot. Those are noteworthy red flags for investors.
Here's Why Codexis Fell as Much as 20.0% Today
The enzyme engineering company reported disappointing full-year 2019 operating results.
What to Watch When Codexis Reports 2019 Operating Results
The stock has tumbled to start 2020. Can the next business update provide any relief to shareholders?
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Valuation
Earnings Transcripts
Codexis Inc (CDXS) Q3 2021 Earnings Call Transcript
CDXS earnings call for the period ending September 30, 2021.
Codexis(CDXS) Q1 2020 Earnings Call Transcript
CDXS earnings call for the period ending March 31, 2020.
Codexis(CDXS) Q4 2019 Earnings Call Transcript
CDXS earnings call for the period ending December 31, 2019.
Codexis(CDXS) Q3 2019 Earnings Call Transcript
CDXS earnings call for the period ending September 30, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.